Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule dire… Read more
Ovid Therapeutics Inc (OVID) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.288x
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has a cash flow conversion efficiency ratio of -0.288x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.87 Million) by net assets ($44.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ovid Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Ovid Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ovid Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovid Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Yingfeng Technology Co Ltd
SHG:605055
|
N/A |
|
ECS ICT Bhd
KLSE:5162
|
-0.079x |
|
Progate Group Corporation
TWO:8227
|
0.017x |
|
Alta Equipment Group Inc
NYSE:ALTG
|
0.862x |
|
CSB Bancorp Inc
PINK:CSBB
|
0.046x |
|
Chen Full International Co Ltd
TWO:8383
|
-0.027x |
|
ONWARD MEDICAL BV EO -12
F:63E
|
N/A |
|
Suven Life Sciences Limited
NSE:SUVEN
|
-0.368x |
Annual Cash Flow Conversion Efficiency for Ovid Therapeutics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Ovid Therapeutics Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.23 Million | $-55.96 Million | -0.820x | -57.29% |
| 2023-12-31 | $87.80 Million | $-45.78 Million | -0.521x | -24.89% |
| 2022-12-31 | $132.27 Million | $-55.23 Million | -0.418x | -163.27% |
| 2021-12-31 | $179.75 Million | $118.61 Million | 0.660x | +155.82% |
| 2020-12-31 | $43.63 Million | $-51.58 Million | -1.182x | -62.04% |
| 2019-12-31 | $70.02 Million | $-51.09 Million | -0.730x | +37.85% |
| 2018-12-31 | $38.81 Million | $-45.56 Million | -1.174x | -211.27% |
| 2017-12-31 | $83.44 Million | $-31.47 Million | -0.377x | -4.44% |
| 2016-12-31 | $49.29 Million | $-17.80 Million | -0.361x | -348.12% |
| 2015-12-31 | $68.07 Million | $-5.49 Million | -0.081x | -46.14% |
| 2014-12-31 | $4.74 Million | $-261.28K | -0.055x | -- |